Instead of the traditional lab-to-clinic pipeline, a "reverse translation" approach uses AI to analyze data from patients who fail standard-of-care treatments. This identifies the specific unmet need and biological target first, guiding subsequent lab research for higher success rates.

The endgame for CZI's work is hyper-personalized, "N of one" medicine. Instead of the current empirical approach (e.g., trying different antidepressants for months), AI models will simulate an individual's unique biology to predict which specific therapy will work, eliminating guesswork and patient suffering.

We possess millions of data points on interventions, but they are useless to AI models because they're trapped in thousands of disparate EMRs in varied formats. The challenge is not generating more data, but solving the human incentive and alignment problems required to create unified data registries.

AI's most significant impact won't be on broad population health management, but as a diagnostic and decision-support assistant for physicians. By analyzing an individual patient's risks and co-morbidities, AI can empower doctors to make better, earlier diagnoses, addressing the core problem of physicians lacking time for deep patient analysis.

AI serves as a powerful health advocate by holistically analyzing disparate data like blood work and symptoms. It provides insights and urgency that a specialist-driven system can miss, empowering patients in complex, under-researched areas to seek life-saving care.

Long before the current hype, a 2005 AI project used electronic medical records and genomic data to find children with an ultra-rare disease who would have otherwise died before age 10. This highlights AI's long-standing, life-saving impact beyond recent commercial applications.

AI platforms can analyze existing medical images, like CT scans ordered for a cough, to find subtle, early signs of cancers. This repurposes vast amounts of routine diagnostic data into a powerful, passive screening tool, allowing for incidental discoveries of diseases like pancreatic cancer without new procedures.

By feeding an AI agent diverse personal data—diet logs, sleep tracking, bloodwork, and genetics—it can identify complex health issues that elude general advice. The AI can find "needle in the haystack" answers, like connecting restless leg syndrome to Swedish ancestry, offering hyper-personalized insights.

The AI platform discovers patterns in patient movement that expert clinicians felt were significant but couldn't objectively measure. This process of data-driven confirmation helps build trust and accelerates the adoption of AI tools by providing evidence for long-held clinical instincts, turning a subjective feeling into objective proof.